Literature DB >> 7240346

Comparative study on human pharmacokinetics of activated ifosfamide and cyclophosphamide by a modified fluorometric test.

T Wagner, D Heydrich, T Jork, G Voelcker, H J Hohorst.   

Abstract

The activated metabolites of ifosfamide and cyclophosphamide (4-hydroxy-ifosfamide and 4-hydroxy-cyclophosphamide) were analysed fluorometrically by condensation of liberated acrolein with m-aminophenol yielding 7-hydroxyguinoline. Interfering fluorescence of blood and urine was eliminated by extraction with dichlormethane and determination of blanks in which the liberated acrolein reacted with hydrazine to non-fluorescent pyrazoline. The modified test proved effective in identifying low levels of activated metabolites in man. After i.v. injection of 20 mg/kg cyclophosphamide or ifosfamide peak levels of activated cyclophosphamide (4.7 nmol/ml) and the area under the curve (c.t = 16.7 nmol.ml/h) showed mean values three times higher than those found for activated ifosfamide. One per cent of the applied dosis of cyclophosphamide vs. 0.3% of ifosfamide was excreted as activated metabolites. Due to the high stability of activated cyclophosphamide and ifosfamide in urine a low liberation rate of acrolein was found, the concentration of which in urine was below 0.5 nmol/ml. Acrolein, which was directly liberated from activated cyclophosphamide or ifosfamide, does not seem to play an important role in the urotoxicity of these cytostatics.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7240346     DOI: 10.1007/bf00405906

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  21 in total

1.  Studies on the clinical pharmacology and toxicology of isophosphamide (NSC-109724).

Authors:  P J Creaven; L M Allen; M H Cohen; R L Nelson
Journal:  Cancer Treat Rep       Date:  1976-04

2.  Isolation and mass spectral identification of blood metabolites of cyclophosphamide: evidence for phosphoramide mustard as the biologically active metabolite.

Authors:  R F Struck; M C Kirk; M H Witt; W R Laster
Journal:  Biomed Mass Spectrom       Date:  1975-02

3.  Identification of aldophosphamide as a metabolite of cyclophosphamide in vitro and in vivo in humans.

Authors:  C Fenselau; M N Kan; S S Rao; A Myles; O M Friedman; M Colvin
Journal:  Cancer Res       Date:  1977-08       Impact factor: 12.701

4.  Fluorometric determination of acrolein and related compounds with m-aminophenol.

Authors:  R A Alarcon
Journal:  Anal Chem       Date:  1968-09       Impact factor: 6.986

5.  [Isolation and characterisation of two main metabolites of ifosfamide from human urine (author's transl)].

Authors:  K Norpoth; G Müller; H Raidt
Journal:  Arzneimittelforschung       Date:  1976

6.  Mass spectrometric characterization of activated N-(2-chloroethyl)amino oxazaphosphorine derivative.

Authors:  M Przybylski; H Ringsdorf; U Lenssen; G Peter; G Voelcker; T Wagner; H J Hohorst
Journal:  Biomed Mass Spectrom       Date:  1977-08

7.  Permeation of cyclophosphamide (NSC-26271) metabolites into tumor cells.

Authors:  U Draeger; H J Hohorst
Journal:  Cancer Treat Rep       Date:  1976-04

8.  Studies on 4-hydroperoxycyclophosphamide (NSC-181815): a simple preparation method and its application for the synthesis of a new class of "activated" sulfur-containing cyclophosphamide (NSC-26271) derivatives.

Authors:  G Peter; T Wagner; H J Hohorst
Journal:  Cancer Treat Rep       Date:  1976-04

9.  Deactivation of cyclophosphamide (NSC-26271) metabolites by sulfhydryl compounds.

Authors:  J Draeger; G Peter; H J Hohorst
Journal:  Cancer Treat Rep       Date:  1976-04

10.  The problem of oncostatic specificity of cyclophosphamide (NSC-26271): Studies on reactions that control the alkylating and cytotoxic activity.

Authors:  H J Hohorst; U Draeger; G Peter; G Voelcker
Journal:  Cancer Treat Rep       Date:  1976-04
View more
  19 in total

Review 1.  Ifosfamide/mesna. A review of its antineoplastic activity, pharmacokinetic properties and therapeutic efficacy in cancer.

Authors:  K L Dechant; R N Brogden; T Pilkington; D Faulds
Journal:  Drugs       Date:  1991-09       Impact factor: 9.546

2.  The effect of age on the pharmacokinetics of ifosfamide.

Authors:  M J Lind; J M Margison; T Cerny; N Thatcher; P M Wilkinson
Journal:  Br J Clin Pharmacol       Date:  1990-07       Impact factor: 4.335

3.  The effect of route of administration and fractionation of dose on the metabolism of ifosfamide.

Authors:  M J Lind; H L Roberts; N Thatcher; J R Idle
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

4.  Comparative effects of ASTA Z 7557 (INN mafosfamide) and cyclophosphamide on hematopoiesis in mice.

Authors:  M R Nowrousian; C G Schmidt
Journal:  Invest New Drugs       Date:  1984       Impact factor: 3.850

5.  Preclinical pharmacokinetics and stability of isophosphoramide mustard.

Authors:  J J Zheng; K K Chan; F Muggia
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

6.  Effect of ASTA Z 7557 (INN mafosfamide) a precursor of 4-hydroxy-cyclophosphamide on human T-lymphocytes' Fc-receptors and immunoregulatory functions.

Authors:  J G Saal; M Hadam; F Frank; H Rautenstrauch; P Fritz
Journal:  Invest New Drugs       Date:  1984       Impact factor: 3.850

7.  Pharmacokinetics and metabolism of cyclophosphamide administered after total body irradiation of bone marrow transplant recipients.

Authors:  U Schuler; P Waidelich; H Kolb; T Wagner; G Ehninger
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

Review 8.  Dosing and side-effects of ifosfamide plus mesna.

Authors:  W P Brade; K Herdrich; U Kachel-Fischer; C E Araujo
Journal:  J Cancer Res Clin Oncol       Date:  1991       Impact factor: 4.553

9.  Metabolism and pharmacokinetics of oral and intravenous ifosfamide.

Authors:  V Kurowski; T Cerny; A Küpfer; T Wagner
Journal:  J Cancer Res Clin Oncol       Date:  1991       Impact factor: 4.553

10.  Ambulatory high-dose 5-day continuous-infusion ifosfamide combination chemotherapy in advanced solid tumors: a feasibility study.

Authors:  T M Loeffler; F W Weber; T U Hausamen
Journal:  J Cancer Res Clin Oncol       Date:  1991       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.